Floatz logo

(1S,2R)-MILNACIPRAN

Major Depressive Disorder

AllerganSmall moleculePhase 4 / ApprovedDormant
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
81/ 100
Competitive Position
65/ 100

Competitive context

235 Active assets in the Major Depressive Disorder cohort.

Asset / SponsorPhaseRating
Zelapar
Corium Innovations, Inc.
Phase 4BBB
Risperdal
Johns Hopkins University
Phase 4BBB
EDIVOXETINE
Eli Lilly and Company
Phase 3BBB
S-Ketamine
Janssen Research & Development, LLC
Phase 4BBB
Vortioxetine
Mayo Clinic
Phase 4BBB

View all 50 →

Same molecule, other indications

(1S,2R)-MILNACIPRAN is also rated in:

depressive disorderDormant
B
Indicative ·
57 / 100
View asset →
ischemic strokeDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →